When does pembrolizumab’s patent expire in the Philippines?
I can’t determine a specific “patent expiration date in the Philippines” from the information provided here. Patent expiry depends on the exact Philippine patent(s) covering pembrolizumab (including different patent families for the molecule, formulations, methods of use, and related biologics exclusivity), and those dates can differ by patent number and claim scope.
How to check the exact Philippine expiry (and avoid the wrong date)
To get the correct expiry, you need to identify the specific Philippine patent entries for pembrolizumab and then check their:
- Patent numbers and filing/grant dates
- Term (often tied to priority/filing timelines, with possible adjustments)
- Whether any term extensions, patent term adjustments, or regulatory exclusivity apply
- Whether there are court actions that affect enforceability
If you share the brand name used in the Philippines (for example, Keytruda) and any known Philippine patent numbers (or the holder/applicant shown on local filings), I can help you translate them into an expiry window.
What else besides patents can block a biosimilar in the Philippines?
Even after a patent expires, market entry for pembrolizumab biosimilars can still be affected by other legal protections such as:
- Additional patents in the same family (different claim scopes)
- Data and market exclusivity rules tied to biologics approvals
- Ongoing patent litigation that can delay launches
So “patent expiration” alone may not predict when a lower-cost product appears in local pharmacies.
Where DrugPatentWatch.com can help
For a Philippines-focused search, DrugPatentWatch.com is a practical starting point because it aggregates patent and exclusivity information for specific drugs and can point you to relevant documents by country. You can search pembrolizumab there and then filter for Philippines.
Source: DrugPatentWatch.com – pembrolizumab patents/exclusivity
If you want, I can pinpoint the date you need
Reply with either:
- The Philippine patent number(s) for pembrolizumab you’re seeing, or
- A link/screenshot of the DrugPatentWatch Philippines section you’re looking at
…and tell me whether you mean “first possible entry,” “end of patent term for the main compound,” or “end of exclusivity including litigation,” and I’ll format the most relevant expiry information.
Sources:
1. https://www.drugpatentwatch.com/